Rheumatoid arthritis is a chronic autoimmune condition where the immune system erroneously attacks joint synovium, causing inflammation, cartilage degradation, and bone erosion.
Rheumatoid arthritis is a chronic autoimmune condition where the immune system erroneously attacks joint synovium, causing inflammation, cartilage degradation, and bone erosion. Stem-cell investigations, primarily using placental mesenchymal stem cells, explore whether these cells can modulate the underlying immune dysregulation and reduce synovial inflammation. MSCs secrete immunosuppressive cytokines and may shift macrophage polarisation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotypes. With 43 registered trials and 7 currently recruiting, the therapeutic premise differs from muscular dystrophy: rather than direct tissue regeneration, MSCs aim to suppress the aberrant T-cell and B-cell responses driving the disease. Early clinical data suggest potential for joint-specific injection or systemic administration to reduce disease activity scores and inflammation markers.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €9,200–€23,000 (bookinghealth.com) |
| 研究的主要细胞类型 | 羊膜膜中的间充质干细胞 |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 43 · 7 recruiting now |
For the clinic's own description, see how Stem Plus describes its Rheumatoid Arthritis programme ↗.
Clinical evidence in rheumatoid arthritis shows encouraging preliminary signals. Seven recruiting trials indicate sustained clinical interest and patient demand. Published trials have documented reductions in serum inflammatory markers (IL-6, TNF-α) and improvements in Disease Activity Score (DAS28) following MSC infusion, with some patients achieving low-disease-activity remission. However, many studies are small and uncontrolled, lacking the rigorous blinding and long-term follow-up expected of modern rheumatology trials. Comparisons with established DMARDs (disease-modifying antirheumatic drugs) are sparse; MSCs may complement rather than replace conventional immunosuppression. Relapse following initial improvement occurs in a proportion of participants, particularly when conventional therapy is withdrawn.
Depending on assessment, a Rheumatoid Arthritis protocol may draw on:
Rheumatoid arthritis stem-cell treatment costs typically range €3,500–6,500 per infusion, depending on cell source, expansion scale, and delivery route. Intra-articular injection into one or few joints is less expensive than systemic administration. Placental MSCs are favoured for cost-efficiency and immunogenicity profile relative to other sources. Disease duration and number of affected joints may influence whether monotherapy or repeat infusions are proposed. European programmes in Italy, Germany, and Spain generally charge at the lower end; private boutique clinics may exceed €7,000. Some trial sites offer treatments at reduced cost to enrolled participants.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Rheumatoid Arthritis cost-by-country breakdown, or compare the best countries for Rheumatoid Arthritis →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Rheumatoid Arthritis.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估